Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer
Author:
Affiliation:
1. Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York
2. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference19 articles.
1. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression;Andius;BJU Int,2004
2. Local BCG failures in superficial bladder cancer;Herr;Eur Urol,1991
3. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial;Herr;J Clin Oncol,1995
4. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder;Lamm;N Engl J Med,1991
5. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006
Cited by 138 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08
2. Prognostic Values of Inflammatory Markers in Patients with High-grade Lamina Propria-invasive Bladder Cancer;The Bulletin of Urooncology;2024-04-04
3. Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy;Cancers;2024-04-02
4. The Effect of Lymphovascular Invasion on Short-Term Tumor Recurrence and Progression in Stage T1 Bladder Cancer;Cureus;2024-02-24
5. Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023;Journal of Urologic Oncology;2023-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3